RxDoctor Payments Data

Asheesh Dewan, MD

Pediatric Endocrinology · Las Vegas, NVNPI 1740352699

Payments from drug & device makers

$1,074,922in general payments, 2019–2025

Across 1,295 payments — averaging $830.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$296K
  • Novo Nordisk$183K
  • Mannkind Corporation$168K
  • Ascendis Pharma Endocrinology Inc$142K
  • Abbott$111K
  • Novo Nordisk AS$110K
  • plus $65K from 46 others
$183in research payments, 2019–2025

Across 3 payments — averaging $60.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mannkind Corporation$183

What the payments were for

  • Consulting fees$30,41711%
  • Speaking & faculty fees$197,76772%
  • Travel & lodging$26,05010%
  • Food & beverage$18,8527%
  • Education$890%
  • Gifts$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric endocrinology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$9,875
Medicare patients
40
Services billed
131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$88,734
MounjaroTirzepatide55$74,365
TrulicityDulaglutide27$33,874
JardianceEmpagliflozin30$29,024
Tresiba Flextouch U-200Insulin Degludec19$20,540
Lyumjev Kwikpen U-100Insulin Lispro-Aabc11$17,527
FarxigaDapagliflozin Propanediol15$8,703
Novolog FlexpenInsulin Aspart24$5,851
Advocate Pen NeedlePen Needle, Diabetic19$5,632
VascepaIcosapent Ethyl11$3,928
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$3,219
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,534
Alcohol Prep PadsAlcohol Antiseptic Pads16$1,648
Testosterone Cypionate16$599
Ondansetron OdtOndansetron20$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$301$108,23982 claims
Novo NordiskOzempic$182,560$88,73477 claims
Boehringer IngelheimJardiance$37$29,02430 claims
AstraZenecaFarxiga$1,525$8,70315 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$76$44873 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric endocrinology providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other pediatric endocrinology in Las Vegas

Where these figures come from

Is this you, or does something look wrong? →